Physician profile
Bilal Malik
NPI 1619926375
$44,463.30
in general payments reported to CMS, 2019-2025
35 companies · $6,261 in 2025
The $6,261 reported for 2025 was more than what 85% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,320 · 2020: $8,533 · 2021: $7,702 · 2022: $3,914 · 2023: $2,729 · 2024: $7,005 · 2025: $6,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $4,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,750.00 |
| Food and Beverage | $4,244.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36,903.46 | 2019-2025 | Lifevest |
| Medtronic, INC. | $1,763.35 | 2021-2025 | Onyx Frontier, Corevalve Evolut R, Intellis Adaptivestim |
| Amgen INC. | $664.02 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $516.60 | 2019-2025 | |
| Abiomed | $457.09 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $450.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $419.68 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $359.25 | 2019-2025 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $303.10 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $277.06 | 2019-2020 | |
| Shockwave Medical, INC | $237.95 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $217.03 | 2024-2025 | Igt Devices Undivided, (P88) Igt Devices Fm, (Bq9) Coronary Ivus |
| Abbott Laboratories | $192.42 | 2021-2024 | Proclaim, Jeti |
| Boston Scientific Corporation | $156.46 | 2021-2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $155.69 | 2024-2025 | Amvuttra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $137.70 | 2025 | Preveleak |
| Sanofi-Aventis U.S. LLC | $132.04 | 2019-2022 | |
| Acist Medical Systems, INC. | $131.46 | 2022 | |
| Penumbra, INC. | $131.36 | 2019-2023 | Indigo System |
| Kiniksa Pharmaceuticals International, Plc | $100.36 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $96.81 | 2024-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $88.85 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.35 | 2019-2024 | Jardiance |
| Cook Medical LLC | $77.73 | 2019-2025 | Zenith Alpha |
| Chiesi USA, INC. | $76.64 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $59.63 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $52.28 | 2019-2022 | |
| Amarin Pharma, INC. | $42.54 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $42.37 | 2023 | Arcalyst |
| Vifor Pharma, INC. | $38.27 | 2019-2021 | |
| Scpharmaceuticals INC. | $25.86 | 2025 | |
| Abbvie INC. | $20.35 | 2024 | |
| Atricure, INC. | $19.92 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| W. L. Gore & Associates, INC. | $15.63 | 2024 | Gore Cardioform Septal Occluder |
| Astellas Pharma US INC | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.